SP1
Transcription factor Sp1
Also known as: SP1_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P08047
- Gene
- SP1
- Ensembl
- ENSG00000185591
- Chromosome
- 12
- Canonical length
- 785 aa
- Protein class
- Cancer-related genes, Predicted intracellular proteins, Transcription factors
- Subcellular location
- Nucleoplasm
OverviewNCBI Gene
The protein encoded by this gene is a zinc finger transcription factor that binds to GC-rich motifs of many promoters. The encoded protein is involved in many cellular processes, including cell differentiation, cell growth, apoptosis, immune responses, response to DNA damage, and chromatin remodeling. Post-translational modifications such as phosphorylation, acetylation, glycosylation, and proteolytic processing significantly affect the activity of this protein, which can be an activator or a repressor. Three transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Nov 2014]
Canonical amino-acid sequenceUniProt
785 residues, UniProt reviewed canonical sequence.
>P08047|SP1
1 MSDQDHSMDE MTAVVKIEKG VGGNNGGNGN GGGAFSQARS SSTGSSSSTG GGGQESQPSP
61 LALLAATCSR IESPNENSNN SQGPSQSGGT GELDLTATQL SQGANGWQII SSSSGATPTS
121 KEQSGSSTNG SNGSESSKNR TVSGGQYVVA AAPNLQNQQV LTGLPGVMPN IQYQVIPQFQ
181 TVDGQQLQFA ATGAQVQQDG SGQIQIIPGA NQQIITNRGS GGNIIAAMPN LLQQAVPLQG
241 LANNVLSGQT QYVTNVPVAL NGNITLLPVN SVSAATLTPS SQAVTISSSG SQESGSQPVT
301 SGTTISSASL VSSQASSSSF FTNANSYSTT TTTSNMGIMN FTTSGSSGTN SQGQTPQRVS
361 GLQGSDALNI QQNQTSGGSL QAGQQKEGEQ NQQTQQQQIL IQPQLVQGGQ ALQALQAAPL
421 SGQTFTTQAI SQETLQNLQL QAVPNSGPII IRTPTVGPNG QVSWQTLQLQ NLQVQNPQAQ
481 TITLAPMQGV SLGQTSSSNT TLTPIASAAS IPAGTVTVNA AQLSSMPGLQ TINLSALGTS
541 GIQVHPIQGL PLAIANAPGD HGAQLGLHGA GGDGIHDDTA GGEEGENSPD AQPQAGRRTR
601 REACTCPYCK DSEGRGSGDP GKKKQHICHI QGCGKVYGKT SHLRAHLRWH TGERPFMCTW
661 SYCGKRFTRS DELQRHKRTH TGEKKFACPE CPKRFMRSDH LSKHIKTHQN KKGGPGVALS
721 VGTLPLDSGA GSEGSGTATP SALITTNMVA MEAICPEGIA RLANSGINVM QVADLQSINI
781 SGNGFLocalizationUniProt · AlphaFold · HPA
Whether an antibody against SP1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.65
- Highest tissue expression
- 38 nTPM
Expression across tissuesHPA
Tissue
- skin: 38 nTPM
- esophagus: 35 nTPM
- thymus: 34 nTPM
- small intestine: 29 nTPM
- duodenum: 29 nTPM
- tonsil: 28 nTPM
Single-cell type
- neutrophils: 205 nCPM
- urothelial cells: 122 nCPM
- esophageal apical cells: 111 nCPM
- foveolar cells: 96 nCPM
- neutrophil progenitors: 95 nCPM
- adipocytes: 92 nCPM
Immune cell
- neutrophil: 6.9 nTPM
- basophil: 3.1 nTPM
- classical monocyte: 2.6 nTPM
- non-classical monocyte: 2 nTPM
- plasmacytoid DC: 1.8 nTPM
- intermediate monocyte: 1.7 nTPM
Brain region
- cerebellum: 44 nTPM
- white matter: 38 nTPM
- medulla oblongata: 37 nTPM
- basal ganglia: 33 nTPM
- midbrain: 32 nTPM
- pons: 31 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about SP1.
Disease | AutoantibodyPubMed
Conditions in which antibodies against SP1 are reported. Each links to that disease's full target list.
Showing 1 of 2 — disease pages carrying at least 10 antigens.
ReferencesPubMed · IEDB
Publications for SP1 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
13 publications
- Novel autoantibodies in Sjogren's syndrome.
2012 · Clin Immunol · RCR 3.9 · 115 citations - Prevalence of Novel Candidate Sjogren Syndrome Autoantibodies in the Dry Eye Assessment and Management (DREAM) Study.
2018 · Cornea · RCR 1.7 · 27 citations - Evaluation of salivary gland protein 1 antibodies in patients with primary and secondary Sjogren's syndrome.
2014 · Clin Immunol · RCR 1.6 · 38 citations - The Potential Role for Early Biomarker Testing as Part of a Modern, Multidisciplinary Approach to Sjögren's Syndrome Diagnosis.
2017 · Adv Ther · RCR 1.5 · 27 citations - Evaluation of Autoantibodies in Patients with Primary and Secondary Sjogren's Syndrome.
2017 · Open Rheumatol J · RCR 1.3 · 27 citations
Show 8 more
- Analysis of novel Sjogren's syndrome autoantibodies in patients with dry eyes.
2017 · BMC Ophthalmol · RCR 1.2 · 24 citations - Investigation of autoantibodies to SP-1 in Chinese patients with primary Sjögren's syndrome.
2018 · Clin Immunol · RCR 0.9 · 16 citations - Prevalence of Novel Candidate Sjögren Syndrome Autoantibodies in the Penn Sjögren's International Collaborative Clinical Alliance Cohort.
2019 · Cornea · RCR 0.7 · 11 citations - [Diagnostic values of anti-salivary gland protein-1 antibody combined with anti-parotid secretory protein antibody for Sjögren's syndrome].
2024 · Beijing Da Xue Xue Bao Yi Xue Ban · RCR 0.5 · 1 citations - Xerophthalmia of Sjogren's Syndrome Diagnosed with Anti-Salivary Gland Protein 1 Antibodies.
2014 · Case Rep Ophthalmol · RCR 0.2 · 4 citations - The transcriptional activator Sp1, a novel autoantigen.
1997 · Arthritis Rheum · RCR 0.1 · 6 citations - Comparison and clinical analysis of tissue-specific autoantibody levels in primary Sjögren's disease and other connective tissue diseases.
2025 · Clin Exp Rheumatol · 3 citations - Relevance of autoantibodies to carbonic anhydrase 6 (CA6), parotid secretory protein (PSP) and salivary gland protein 1 (SP1) to dry eye disease (DED).
2026 · BMJ Open Ophthalmol
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.1
- gnomAD pLI
- 1
- gnomAD missense Z
- 1.14
- DepMap mean gene effect
- -0.12
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cellular response to estrogen stimulus
- cellular response to insulin stimulus
- cellular response to zinc ion starvation
- host-mediated activation of viral transcription
- positive regulation of amyloid-beta formation
- positive regulation of angiogenesis
- positive regulation of apoptotic signaling pathway
- positive regulation of blood vessel endothelial cell migration
- positive regulation of DNA-templated transcription
- positive regulation of gene expression
- positive regulation of transcription by RNA polymerase II
- positive regulation of vascular endothelial cell proliferation
- regulation of DNA-templated transcription
- regulation of transcription by RNA polymerase II
- response to hydroperoxide
- rhythmic process
- cellular response to wortmannin
- positive regulation of hydrogen sulfide biosynthetic process
Molecular functions
- bHLH transcription factor binding
- DNA binding
- DNA-binding transcription activator activity, RNA polymerase II-specific
- DNA-binding transcription factor activity
- DNA-binding transcription factor activity, RNA polymerase II-specific
- double-stranded DNA binding
- histone acetyltransferase binding
- histone deacetylase binding
- identical protein binding
- molecular adaptor activity
- protein homodimerization activity
- RNA polymerase II cis-regulatory region sequence-specific DNA binding
- RNA polymerase II transcription regulatory region sequence-specific DNA binding
- RNA polymerase II-specific DNA-binding transcription factor binding
- sequence-specific DNA binding
- sequence-specific double-stranded DNA binding
- transcription cis-regulatory region binding
- transcription coregulator binding
- zinc ion binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of SP1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SP1 as an antibody target. Whether an autoantibody or antibody against SP1 could matter depends on whether native SP1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SP1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label SP1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...